ONE of the largest tissue banks in the United States has signed an agreement to use York healthcare company Tissue Regenix’s technology.
Community Tissue Services, which distributes more than 230,000 grafts for transplant annually, will use the patented dCELL technology to produce human biological scaffolds, by “washing” the DNA from tissues for them to be transplanted without being rejected.
The scaffolds will initially be used for acute and chronic wound care, but the partners plan to expand to cover other areas of clinical need.
The partnership with Community Tissue Services will allow Tissue Regenix, which is based on York Science Park, to create dCELL Dermis products in order to target the existing $1.4 billion market for wound healing devices and equipment.
Antony Odell, managing director of Tissue Regenix, said: “This is an important step in our global commercialisation strategy and is a first step in bringing the benefits of dCELL Technology to the US. We remain on course for a US launch of dCELL Dermis in the first half of 2014.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here